search icon
      blog search icon

      bluebird bio, Inc. (BLUE) stock is Popping high in premarket: Here’s Why - Stocks Telegraph

      By Muhammad Ali

      Published on

      December 13, 2021

      1:41 PM UTC

      Last Updated on

      December 13, 2021

      3:42 PM UTC

      bluebird bio, Inc. (BLUE) stock is Popping high in premarket: Here’s Why - Stocks Telegraph

      Shares of the bluebird bio, Inc. (BLUE) stock were popping high in the premarket today on December 13, 2021. The BLUE stock price saw a push of 15.96% to reach $10.39 a share at the time of this writing. The stock was gloomy in the previous trade and went low by 4.48% at closing. Let’s take a closer look to understand the current bullish sentiment.

      What’s Happening?

      A piece of positive news appeared from the BLUE stock today after which the sentiment became positive bullish for this stock today. The news is related to the release of Phase 1/2 HGB-206 results which is the study of lovotibeglogene autotemcel gene therapy in patients with sickle cell disease. Moreover, the bluebird discussed the further analysis of its pivotal cohort, HGB-206 Group C. According to the data, the Group C patients carry off normal levels of key hemolysis markers. Moreover, the treatment showed improvement in the quality of life in patients.

      The published data in the New England Journal of Medicine reflected that the lentiviral gene transfer improves the quality of life of sickle cell disease patients by eliminating the painful and disruptive crises that can occur several times in a single month. Sickle cell is a disease in which a patient does not have enough healthy red blood cells.

      Previous news of BLUE stock:

      On December 12, 2021, BLUE stock released the results for the betibeglogene autotemcel, a gene therapy. The adult and pediatric patients living with β-thalassemia participated in the study. The study demonstrated that such patients could produce normal or near-normal levels of total hemoglobin. Moreover, they can continue to remain transfusion-free, and achieve stable iron markers, through up to seven years of follow-up. The data from the study suggests that the beti-cel is the potential treatment that explains the genetic cause of beta-thal and reduces the practical burden concerned with the disease.

      Financial View of BLUE stock:

      According to the third quarter 2021 financial results, the BLUE stock generated $22.7 million in revenue in the reported quarter. The revenue increased as compared to $19.3 million in the same tenure of the previous year. The BLUE stock spent $131.4 million in R&D expenses and $68.3 million in S&G expenses in the third quarter of 2021. The company suffered a net loss of $216.8 million in the third quarter of 2021.

      Wrap Up:

      Investors are responding positively to the recent announcement of Phase 1/2 HGB-206 results. The progress in the year 2021 is not satisfactory as this stock lost almost 74% year to date.

      More From Stocks telegraph